Suboxone, Belbuca, Zubsolv, commonly prescribed anti-opioid medications, have been linked to a distressing side effect – tooth decay and tooth loss injuries. This unexpected connection has led users to consider Suboxone, Belbuca, and Zubsolv tooth decay lawsuits as a means of seeking compensation for the harm caused. If you or a loved one has suffered tooth loss, tooth decay, or any other type of tooth damage you believe to be linked to Suboxone, Belbuca or Zubsolv use, contact an experienced attorney right away to find out if you are eligible to file a Suboxone lawsuit against the manufacturer.
Individuals who have suffered severe tooth decay, tooth loss, or other dental injuries as a result of Suboxone use may be eligible to pursue legal action against the manufacturers. One of the first lawsuits alleging a link between Suboxone and tooth decay was filed in September 2023, in the U.S. District Court for the Northern District of Ohio. The complaint names as defendants Indivior, Inc., Aquestive Therapeutics, MonoSol Rx, Inc., and Reckitt Benckiser LLC, and alleges that the plaintiff, David Sorensen, suffers from permanent tooth decay and has required extensive dental work as a result of his Suboxone use.
Reports have emerged recently suggesting that the manufacturers knew about the potential for Suboxone to cause tooth decay long before the FDA required new label warnings in 2022. As more information comes to light about this issue, additional lawsuits may be brought against the manufacturers, alleging that the drug causes irreversible tooth decay and tooth loss injuries, leading to significant pain, discomfort, and extensive dental treatments. The manufacturers will likely face complaints that they failed to adequately warn patients and healthcare professionals about the potential risks associated with Suboxone use, causing users to suffer avoidable injuries.
Several manufacturers are involved in the production and distribution of Suboxone and buprenorphine medications. These companies include:
“The U.S. Food and Drug Administration (FDA) is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues.”
Suboxone is a prescription medication used to treat opioid addiction by reducing opioid cravings and withdrawal symptoms, allowing individuals to recover from addiction. It contains a combination of two drugs: buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist. Buprenorphine works by helping to manage cravings and withdrawal symptoms, while naloxone blocks the effects of opioids, making it less likely for a person to misuse the medication. Suboxone is available in two forms: as a tablet and as a sublingual film applied under the tongue.
It is important to note that Suboxone is not a standalone treatment for opioid addiction. Rather, it is typically prescribed as part of a comprehensive treatment program that includes counseling and behavioral therapy. It is intended to help individuals gradually wean off opioids and achieve long-term recovery. And while Suboxone can be an important part of opioid addiction recovery, it can also cause side effects, one of the most serious potential side effects being dental issues like tooth decay and tooth loss.
A successful Suboxone lawsuit could help affected individuals recover compensation for various damages related to their tooth decay or tooth loss injuries. These damages may include:
Recent reports have raised concerns about the link between Suboxone use and tooth decay. The acidic nature of Suboxone, particularly the sublingual films and tablets that dissolve in the mouth, may contribute to dental problems such as tooth decay, tooth loss, infections, and other dental injuries. Patients who have used Suboxone for an extended period have reported experiencing severe dental problems, including cavities, gum disease, and the need for tooth extractions.
In January 2022, the FDA issued a warning highlighting more than 300 cases of tooth decay and dental problems linked to Suboxone and other buprenorphine drugs dissolved in the mouth to treat opioid use disorder (OUD) and pain. These dental problems have been observed in patients as young as 18 years old and in those with no history of dental issues, with some experiencing dental damage just weeks after starting treatment.
In light of these issues, the FDA at that time required a new warning about the risk of dental problems to be added to the prescribing information and the Medication Guide for all buprenorphine-containing medicines dissolved in the mouth.
